Medicine and Dentistry
Systematic Review
100%
Transitional Cell Carcinoma
98%
Meta-Analysis
74%
Cystectomy
72%
Disease
51%
Prostate Cancer
43%
Prostatectomy
38%
Immune Checkpoint Inhibitor
36%
Overall Survival
35%
Network Meta-Analysis
28%
Biological Marker
27%
Nephroureterectomy
26%
Clear Cell Renal Cell Carcinoma
26%
Kidney Metastasis
25%
Neoplasm
25%
Cancer Specific Survival
24%
Pembrolizumab
23%
Logistic Regression Analysis
23%
Upper Urinary Tract
23%
Odds Ratio
22%
Bladder
22%
Bladder Cancer
22%
Urothelial Cancer
21%
Recurrent Disease
20%
Proportional Hazards Model
19%
Hazard Ratio
19%
Decision Making
18%
Systemic Therapy
16%
Lymph Node
16%
Combination Therapy
15%
Biopsy
14%
Urinary Diversion
13%
Extracorporeal
13%
Non Muscle Invasive Bladder Cancer
13%
Diagnosis
13%
Serositis
13%
Radiation Therapy
13%
Immunotherapy
12%
Prognostic Factor
11%
Lymphocyte
10%
Progression Free Survival
10%
Randomized Controlled Trial
9%
Recurrence Free Survival
9%
Malignant Neoplasm
9%
Clinical Decision Making
9%
Subgroup Analysis
9%
Metastatic Carcinoma
9%
Biochemical Recurrence
8%
Postoperative Complication
8%
Radical Surgery
8%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
57%
Immune Checkpoint Inhibitor
48%
Kidney Metastasis
41%
Overall Survival
40%
Chemotherapy
31%
Combination Therapy
23%
Renal Cell Carcinoma
22%
Disease
22%
Pembrolizumab
21%
Biological Marker
20%
Non Muscle Invasive Bladder Cancer
20%
Prostate Cancer
20%
Neoplasm
18%
Adverse Event
16%
Cancer Specific Survival
16%
Malignant Neoplasm
15%
Protein Tyrosine Kinase Inhibitor
14%
Progression Free Survival
14%
Muscle Invasive Bladder Cancer
14%
Immunotherapy
13%
Androgen
13%
Apalutamide
13%
Urokinase
13%
Endocrine Therapy
13%
Recurrent Disease
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
11%
Proton Pump Inhibitor
11%
Cisplatin
10%
Bladder Cancer
8%
Recurrence Risk
8%
Prognosis
7%
Biochemical Recurrence
7%
Cancer Growth
7%
Bladder Tumor
7%
Placebo
7%
Antibiotics
6%
Kidney Cancer
6%
Inflammation
6%
Plasminogen
6%
Castration Resistant Prostate Cancer
6%
Carboplatin
6%
Binding Protein
6%
Paclitaxel
6%
Programmed Cell Death
6%
Scatter Factor
6%
Hepatocyte Growth Factor
6%
First-Line Chemotherapy
6%
Cefditoren Pivoxil
6%
Degarelix
6%
Relugolix
6%
Keyphrases
Meta-analysis
26%
Systematic Meta-analysis
20%
Radical Cystectomy
19%
Upper Tract Urothelial Carcinoma
16%
Plasma Parameters
13%
Preoperative Nomogram
13%
Managerial Decision Making
13%
Apalutamide
13%
Renal Cell Carcinoma
13%
Immune Checkpoint Inhibitors
13%
Metastatic Renal Cell Carcinoma (mRCC)
13%
Prognostic Factors
9%
Oncological Outcomes
9%
Confidence Interval
9%
Overall Survival
8%
Propensity Score Matching
8%
Gross Hematuria
7%
Urinary Tract Infection
7%
Cancer-specific Survival
6%
Vascular Cell Adhesion molecule-1 (VCAM-1)
6%
Pembrolizumab
6%
Steep Trendelenburg Position
6%
Prognosticator
6%
Biomarker Model
6%
Upper Tract Urothelial Cancer
6%
Advanced Renal Cancer
6%
Prognostic Marker
6%
Japan
6%
Preoperative Model
6%
Activator protein-1 (AP-1)
6%
Inflammatory Response Biomarkers
6%
Salvage Radical Prostatectomy
6%
Retrospective multicenter Study
6%
Urinary Bladder Cancer
6%
Bladder Tuberculosis
6%
Tohoku
6%
Metastatic Urothelial Carcinoma
6%
Unfit Patients
6%
Disease Outcome
6%
Geriatric nutritional Risk Index
6%
Cancer Patients
6%
Bladder Cancer
6%
Plasminogen Activation System
6%
Baseline Tumor Size
6%
Systemic Immune-inflammation Index
6%
Hematologic
6%
Multi-institutional Study
6%
Immune Checkpoint Inhibitor Combination Therapy
6%
Definitive Therapy
6%
Testosterone Recovery
6%